CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
BT062drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01001442
NCT01001442Phase 2Completed
CompareCT.gov

A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma

Biotest Pharmaceuticals Corporation·interventional·Posted Oct 26, 2009·Updated Jul 30, 2019

In Brief

A Phase 2 clinical trial evaluating BT062 for Multiple Myeloma. Completed, enrolled 35 participants across 5 sites.

Detailed Summary

This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsBiotest

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 26, 2009
Enrollment StartAug 1, 2010
Primary CompletionJul 1, 2014
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.7 years ago

Interventions

BT062drug

intravenous administration